Treatment Options for Juvenile Idiopathic Arthritis (JIA) Associated Uveitis

REFERENCES

• Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm. 2013;21(6):478–485.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Heinz C, Edelsten C, et al. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm. 2013;21(3):180–191.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Heiligenhaus A, deBoer J, et al. Controversies in juvenile idiopathic arthritis-associated uveitis. Ocul Immunol Inflamm. 2013;21(3):167–179.
   PubMed Web of Science ®Google Scholar
• Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2003;14:395–398.
   PubMedGoogle Scholar
• Thorne JE, Woreta F, Kedhar SR, et al. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmology. 2007;143:840–846.
   PubMed Web of Science ®Google Scholar
• Dana MR, Merayo-Lloves J, Schaumberg DA, et al. Visual outcomes prognosticators in juvenile rheumatoid arthritis- associated uveitis. Ophthalmology. 1997;104:236–244.
   PubMed Web of Science ®Google Scholar
• Kump LI, Castañeda RA, Androudi SN, et al. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology. 2006;113:1874–1877.
   PubMed Web of Science ®Google Scholar
• Yu EN, Meniconi ME, Tufail F, et al. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid- resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm. 2005;13:353–360.
   PubMed Web of Science ®Google Scholar
• Woreta F, Thorne JE, Jabs DA, et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647–655.
   PubMed Web of Science ®Google Scholar
• Edelsten C, Lee V, Bentley CR, et al. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002;86:51–56.
   PubMed Web of Science ®Google Scholar
• Chen CS, Roberton D, Hammerton ME. Juvenile arthritis associated uveitis: visual outcomes and prognosis. Can J Ophthalmol. 2004;39:614–620.
   PubMed Web of Science ®Google Scholar
• Kotaniemi K, Savolainen A, Karma A, et al. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol. 2003;48:489–502.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol. 2004;31:390–392.
   PubMed Web of Science ®Google Scholar
• Key SN, Kimura SJ. Iridocyclitis associated with juvenile rheumatoid arthritis. Am J Ophthalmology. 1975;80:425–429.
   PubMed Web of Science ®Google Scholar
• Ozdal PC, Vianna RN, Deschenes J. Visual outcomes of juvenile rheumatoid arthritis–associated uveitis in adults. Ocul Immunol Inflamm. 2005;13:33–38.
   PubMed Web of Science ®Google Scholar
• Zulian F, Martini G, Falcini F, et al. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol. 2002;29:2446–2253.
   PubMed Web of Science ®Google Scholar
• Chia A, Lee V, Graham EM, et al. Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol. 2003;135:757–762.
   PubMed Web of Science ®Google Scholar
• Paroli MP, Abbouda A, Restivo L. Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications. Ocul Immunol Inflamm. 2015;23(1):74–81.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Thme N, Horneff G. Methotrexate is protective against the new onset of uveitis under etanercept treatment. Data from the German Etanercept Registry. Ann Rheum. 2010;69(3):626.
   Google Scholar
• Thorne JE, Woreta FA, Dunn JP, et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–1441.
   PubMed Web of Science ®Google Scholar
• Slabaugh MA, Herlihy E, Ongchin S, et al. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol. 2012;153(5):932–938.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Holbrook JT, Ansari H, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology. 2013;120(8):1571–1579.
   PubMed Web of Science ®Google Scholar
• Gregory AC II, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120(1):186–192.
   PubMed Web of Science ®Google Scholar
• Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis. F1000Prime Rep. 2014;6:41.
   PubMedGoogle Scholar
• Bratton ML, He YG, Weakley DR. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. J AAPOS. 2014;18(2):110–113.
   PubMed Web of Science ®Google Scholar
• Kochar R, Kyle M, Walsh KM, et al. Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment. Rheumatol Int. 2012;32:3055–3060.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362–365.
   PubMed Web of Science ®Google Scholar
• Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr. 1998;133:266–268.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Mingels A, Heinz C, et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17:743–748.
   PubMed Web of Science ®Google Scholar
• Ayuso VK, van de Winkel EL, Rothova A, et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151:217–222.
   PubMed Web of Science ®Google Scholar
• Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95:209–213.
   PubMed Web of Science ®Google Scholar
• Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91:180–184.
   PubMed Web of Science ®Google Scholar
• Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25(4):427–435.
   PubMed Web of Science ®Google Scholar
• Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416–1421.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond). 2009;23:1192–1198.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–796.
   PubMed Web of Science ®Google Scholar
• Bou R, Iglesias E, Antón J. Treatment of uveitis associated with juvenile idiopathic arthritis. Curr Rheumatol Rep. 2014;16(8):437.
   Web of Science ®Google Scholar
• Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81.
   PubMedGoogle Scholar
• Zhao Y, Wallace C. Judicious use of biologicals in juvenile idiopathic arthritis. Curr Rheumatol Rep. 2014;16(11):454.
   Web of Science ®Google Scholar
• Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252–257.
   PubMed Web of Science ®Google Scholar
• Lovell D. Biological agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatric Drugs. 2004;6:137–146.
   PubMedGoogle Scholar
• Gartlehner G, Hansen RA, Jonas BL, et al. Biologics for the treatment of juvenile idiopathic arthritis: a systemic review and critical analysis of the evidence. Clin Rheumatol. 2008;27:67–76.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm. 2013;21(1):19–27.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Arcidiacono B, Nascimbeni G, et al. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug Des Devel Ther. 2014;8:341–348.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Benton D, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014;15:14.
   PubMed Web of Science ®Google Scholar
• Magli A, Forte R, Navarro P, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1601–1606.
   PubMed Web of Science ®Google Scholar
• Bravo-Ljubetic L, Peralta-Calvo J, Noval S, et al. Adalimumab therapy for refractory childhood uveitis. J AAPOS. 2013;17:456–459.
   PubMed Web of Science ®Google Scholar
• Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23.
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology. 2006;45:982–989.
   PubMed Web of Science ®Google Scholar
• Tynjälä P, Lindhal P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548–550.
   PubMed Web of Science ®Google Scholar
• Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Opthalmol. 2007;144:844–849.
   PubMed Web of Science ®Google Scholar
• Kahn P, Weiss M, Imundo LF, et al. favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860–864.
   PubMed Web of Science ®Google Scholar
• Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308–314.
   PubMed Web of Science ®Google Scholar
• Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threateningchildhood uveitis. Rheumatology. 2008;47:1510–1514.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146–1150.
   PubMed Web of Science ®Google Scholar
• La Torre F, Cattalini M, Teruzzi B, et al. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series. BMC Res Notes. 2014;24:7:316.
   Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.
   PubMed Web of Science ®Google Scholar
• Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. 2008;47:339–344.
   PubMed Web of Science ®Google Scholar
• Kotaniemi K, Säilä H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–1429.
   PubMedGoogle Scholar
• Schmeling H, Minden K, Foeldvari I, et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014;66(9):2580–2589.
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–324.
   PubMed Web of Science ®Google Scholar
• Doycheva D, Zierhut M, Blumenstock G, et al. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol. 2014;98(4):523–528.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol. 2013;11:16.
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1 year follow-up data from the Italian Registry. J Rheumatol. 2013;40:70–79.
   Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31:320–321.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90–95.
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:297–300.
   PubMed Web of Science ®Google Scholar
• Zulian F, Balzarin F, Falcini F, et al. Abatacept for severe anti–tumor necrosis factor alpha refractory juvenile idiopathic arthritis–related uveitis. Arthritis Care & Research. 2010;62(6):821–825.
   PubMed Web of Science ®Google Scholar
• Zulian F, Zannin ME. Abatacept for refractory juvenile idiopathic arthritis–associated uveitis: two new cases. Comment on the article by Zulian, et al., in Arthritis Care & Research. 2010;62(6):821–825. Arthritis Care Res. 2011;63:307–310.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2015;42(4):706–711.
   PubMed Web of Science ®Google Scholar
• Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22(2):155–157.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology. 2011;50:1390–1394.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmune Rev. 2011;11(1):35–39.
   PubMed Web of Science ®Google Scholar
• Sen ES, Sharma S, Hinchcliffe, et al. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease – a case cohort interventional study. Rheumatology. 2012;51:2199–2203.
   PubMed Web of Science ®Google Scholar
• Tarkiainen M, Tynjälä P, Vähäsalo P, et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford). 2014; 54(7):1170–1176.
   PubMed Web of Science ®Google Scholar
• Foell D, Wulffraat N, Wedderburn LR. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission a randomized clinical trial. JAMA Ophthalmol. 2010;303(13):1266–1273.
   Web of Science ®Google Scholar
• Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014;22(2):96–101.
   PubMed Web of Science ®Google Scholar